Should I buy Biogen (BIIB) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $231 (+0.9 %), call made on July 31, 2026, maturing on July 31, 2027 (75 d ago).
Firm-by-firm track record on Biogen
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| B of A Securities | 57 % | +18.8 % | 7 | $215 -6% |
| Canaccord Genuity | 43 % | +10.1 % | 14 | $248 +8% |
| Citigroup | 71 % | +10.0 % | 14 | $215 -6% |
| Barclays | 33 % | +3.2 % | 6 | $200 -13% |
| RBC Capital | 33 % | -0.6 % | 30 | $256 +12% |
| Truist Securities | 45 % | -2.4 % | 11 | $235 +3% |
| Morgan Stanley | 34 % | -3.1 % | 47 | $231 +1% |
| UBS | 38 % | -3.3 % | 8 | $270 +18% |
✅ Reasons to believe
- 68% of analysts rate it a buy (Buy consensus, 19 ratings) — a sign of market conviction.
- 8 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- Even the most reliable firm on BIIB, Citigroup (71% hit rate, 14 scored calls), only targets $215 (call made on August 3, 2026, maturing on August 3, 2027) (-6%) in its most recent call, and $190 (call made on April 13, 2026, maturing on April 13, 2027) (-17%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 19 ratings, 5 are neutral and 1 is a sell.
- Limited upside: the median target is only +7% from the current price.
- High valuation (P/E ~41): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on BIIB
Median target $245 (+7%) · 19 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Biogen now?
We won't decide for you. The facts: 68% of analysts rate it a buy, median target $245 (+7%), and Citigroup (most reliable on BIIB, 71%) targets $215. Weigh that against valuation (P/E ~41). This is not personalized advice.
Is it too late to invest in Biogen?
Not according to analysts: the median target ($245) is still +7% above the current price ($229) (most reliable on BIIB: Citigroup, 71%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Biogen still worth investing in?
It depends on the gap between the price ($229) and its estimated value: analysts target $245 on median (+7%), with 68% buys (most reliable on BIIB: Citigroup, 71%). Cross-check with their real reliability on BIIB and the cautions above. Information, not advice.
What's the main risk in buying BIIB?
Even the most reliable firm on BIIB, Citigroup (71% hit rate, 14 scored calls), only targets $215 (call made on August 3, 2026, maturing on August 3, 2027) (-6%) in its most recent call, and $190 (call made on April 13, 2026, maturing on April 13, 2027) (-17%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Biogen profile (consensus, analyst reliability, price target, performance).